A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Inclusion Criteria:

- Healthy male or female 18 to 65 years of age at Screening, inclusive

- Body mass index (BMI) 18.5 to 32 kg/m^2, inclusive

- Body weight 50 to 100 kg, inclusive

- Females must be of non-childbearing potential

- Males of reproductive potential must agree to remain abstinent or must be using
highly effective contraception and must avoid sperm donation, from Screening until at
least 8 weeks after the last study drug administration or until study completion,
whichever is later

Exclusion Criteria:

- Significant medical history, psychiatric disorder, or acute infection at Screening
(as determined by Investigator)

- History of alcoholism or drug addiction within 6 months prior to CRU Check-in

- Use of tobacco or nicotine-containing products from 6 months prior to CRU Check-in
and during the study

- Participation in any other investigational study drug trial in which receipt of an
investigational study drug occurred wtihin 30 days or 5 half-lives, whichever is
longer, prior to CRU Check-in